Healthcare
Abcam plc(ABCM)
Live Price
Offline$23.99
+0.04% today
1Y Change
—
Window
No data
- Market Cap
- $5.52B
- Revenue Growth
- -43.2%
- EPS Growth
- -135.3%
- Dividend Yield
- 0.0%
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abcam plc (ABCM) is a Healthcare stock with a market cap of $5.52B and listed on NASDAQ. The stock last traded around $23.99. Baseline metrics include revenue growth of -43.2%, EPS growth of -135.3%, a dividend yield of 0.0%. What stands out right now is revenue -43.2%, EPS -135.3%, free cash flow -118.5% with operating margin 2.0% and ROIC 0.6%. Valuation already assumes a fairly strong business story at P/E 578.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ABCM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-43.2% vs +7.6% peer median
Operating Margin
Below sector median
+2.0% vs +19.4% peer median
P/E
Above sector median
578.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Aug 31, 2023, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -43.2% and EPS is at -135.3%, with operating margin around 2.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ABCM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ABCM Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ABCM and SPY.
Company Overview
Abcam plc
NASDAQ Global Select
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
- Leadership
- Alan Thomas Hirzel BS,
- IPO Date
- Oct 22, 2020
- Employees
- 1.8k
- Street Address
- Discovery Drive
- Mailing
- Cambridge, CB2 0AX
- Region
- Cambridge, GB
- Reporting Currency
- USD
- Investor Line
- 44 12 2369 6000
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 578.4
- EV/EBITDA
- 2.8
- Price/Sales
- —
- Price/Book
- 3.9
Growth
- Revenue
- -43.2%
- EPS
- -135.3%
- Free Cash Flow
- -118.5%
Profitability
- Gross Margin
- 71.2%
- Operating Margin
- 2.0%
- Net Margin
- 1.4%
- ROE
- 0.8%
- ROIC
- 0.6%
Balance Sheet
- Debt/Equity
- 0.35
- Current Ratio
- 1.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.